Brief

The inspection of Biose Industrie's facility in Aurillac, France, conducted from October 15 to 17, 2024, revealed significant non-conformities and deficiencies. A letter dated December 20, 2024, notified the establishment of these issues, which were not satisfactorily resolved by January 10, 2025. The ANSM issued a warning to Biose Industrie regarding several areas of concern: - Ineffective deviation management - Systematic failures in data integrity and traceability - Unresolved requalification issues for equipment and facilities used in active substance production - Continued production of a precursor despite rejected validation procedure The ANSM instructed Biose Industrie to implement corrective actions within specific timeframes, including: * Establishing an effective deviation management system (2 months) * Implementing measures to address data integrity issues in automated systems (6 months) * Conducting requalifications for equipment and facilities used in precursor production (6-9 months) * Finalizing validation of the precursor production procedure (6 months)

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies